The estimated Net Worth of Kathryn J Collier is at least $10.4 Tysiąc dollars as of 25 July 2024. Ms. Collier owns over 4,000 units of Regulus Therapeutics Inc stock worth over $10,380 and over the last 7 years she sold RGLS stock worth over $0. In addition, she makes $0 as Independent Director at Regulus Therapeutics Inc.
Kathryn has made over 2 trades of the Regulus Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently she bought 4,000 units of RGLS stock worth $7,280 on 25 July 2024.
The largest trade she's ever made was buying 7,100 units of Regulus Therapeutics Inc stock on 16 November 2018 worth over $10,011. On average, Kathryn trades about 793 units every 148 days since 2018. As of 25 July 2024 she still owns at least 6,740 units of Regulus Therapeutics Inc stock.
You can see the complete history of Ms. Collier stock trades at the bottom of the page.
Kathryn J. Collier serves as Independent Director of the Company. Since July 2019, Ms. Collier has served as the vice president for audit services of Sempra Energy, a publicly-traded energy services holding company whose subsidiaries provide electricity, natural gas and value-added products and services. In this position, Ms. Collier oversees the internal audit function for Sempra Energy, including the Financial Leadership Program and audit oversight of Sempra’s operating companies. From March 2019 to July 2019, Ms. Collier served as the chief strategy and origination officer for Sempra LNG, a wholly-owned subsidiary of Sempra Energy. From August 2018 to March 2019, Ms. Collier served as chief financial officer and chief administrative officer for Sempra North America Infrastructure. Ms. Collier also previously served as vice president and treasurer for Sempra Energy from April 2012 to August 2018. Prior to joining Sempra Energy in 2012, Ms. Collier held several executive positions within global corporate and investment banking at Bank of America Merrill Lynch. Ms. Collier holds a bachelor’s degree in accounting from Valparaiso University, Valparaiso, Indiana. Our Nominating and Corporate Governance Committee believes that Ms. Collier is qualified to serve on our Board of Directors due to her extensive financial and operational experience, her experience in investment banking and her corporate governance experience with various boards
Kathryn Collier is 52, she's been the Independent Director of Regulus Therapeutics Inc since 2018. There are 7 older and 7 younger executives at Regulus Therapeutics Inc. The oldest executive at Regulus Therapeutics Inc is David Baltimore, 82, who is the Independent Director.
Kathryn's mailing address filed with the SEC is 10614 Science Center Dr, San Diego, CA 92121, USA.
Over the last 12 years, insiders at Regulus Therapeutics Inc have traded over $78,282,075 worth of Regulus Therapeutics Inc stock and bought 65,288,007 units worth $66,275,578 . The most active insiders traders include Forest Baskett, Scott D Sandell oraz Anthony A. Jr. Florence. On average, Regulus Therapeutics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $890,488. The most recent stock trade was executed by Kathryn J Collier on 25 July 2024, trading 4,000 units of RGLS stock currently worth $7,280.
regulus therapeutics inc. (nasdaq:rgls) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting micrornas. regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microrna therapeutics pipeline complemented by a maturing micromarkerssm biomarkers platform and a rich intellectual property estate to retain its leadership in the microrna field. regulus is developing rg-101, a galnac-conjugated anti-mir targeting microrna-122 for the treatment of chronic hepatitis c virus infection, and rg-012, an anti-mir targeting microrna-21 for the treatment of alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy. in addition, rg-125, a galnac-conjugated anti-mir targeting microrna-103/107 for the treatment of nash in patients with type 2 diabetes/pre-diabetes, has entered phase i clinical development through its strategic alliance with astrazeneca. reg
Regulus Therapeutics Inc executives and other stock owners filed with the SEC include: